UCB Presents New Long-Term Data Showing Substantial Impact for CIMZIA® (Certolizumab Pegol) in Axial Spondyloarthritis and Rheumatoid Arthritis and Late-Breaking Bimekizumab Data in Psoriatic Arthritis

Friday, October 19, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

Corporate Communications

France Nivelle,Global Communications, UCB

Investor Relations

Antje Witte, Investor Relations, UCB

Brand Communications

Andrea Levin Christopher,

Immunology Communications, UCB

 

T +32.2.559.9178, france.nivelle@ucb.com

T +32.2.559.94.14, antje.witte@ucb.com

T +1.404.483.7329

andrea.levin@ucb.com

 

Laurent Schots,

Media Relations, UCB   

 

T+32.2.559.92.64, laurent.schots@ucb.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store